OakChart

Euda Health Holdings Limited

EUDAReal Estate·Real Estate Services·Singapore·Nano·NASD·Nov 10 • 3:59 PM ET

14.660.00 (0.00%)
2026-11-11 14:52 CET
Market cap
43.90 USD m
Revenue, TTM
7.23 USD m
Net income, TTM
-2.36 USD m
Free cash flow, TTM
-2.47 USD m
EPS diluted, TTM
-1.16
P/E
-
Compare

Price

EUDA against its 20, 50 and 200-day averages
2050200
10.0020.0030.00394K789KApr 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EUDAclose 14.6620-day 14.9650-day 15.70200-day 15.3614.66

79.4% under 71.20 on 7 Nov 2025. Last 15 sessions, 40.8% high to low

Profile

EUDA
52-week range, 15% of the way up
5.2668.00

EUDA Health Holdings Ltd. engages in the provision of a digital healthcare analytic platform. It operates through Medical Services and Property Management Services segments. The Medical Services segment involves in the healthcare specialty group business offering range of specialty care services to patients, and engaged in the medical facility general practice clinic that provides holistic care for various illnesses. The Property Management Services segment operates in the property management that services shopping malls, business office building, and residential apartments. The company was founded by Kelvin Chen on 2019 is headquartered in Singapore.

Employees123
IPODec 14, 2021
Beta0.57
ATR, 14d1.59
Rel volume0.00
Short float0.37%
Insider own41.17%
Inst own0.00%

Snapshot

6 groups

Valuation

Index-
Market Cap43.90M
Enterprise Value43.86M
Income-2.36M
Sales7.23M
Book/sh2.00
Cash/sh0.12
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees123
IPODec 14, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S6.07
P/B7.35
P/C118.65
P/FCF-
EV/EBITDA-
EV/Sales6.07
Quick Ratio2.53
Current Ratio2.53
Debt/Eq0.06
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.16
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y67.02% -
Sales past 3/5Y-11.50% -8.35%
EPS Y/Y TTM89.18%
Sales Y/Y TTM-
EPS Q/Q-563.66%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own41.17%
Insider Trans0.00%
Inst Own0.00%
Inst Trans0.00%
ROA-39.72%
ROE-208.62%
ROIC-38.74%
Gross Margin47.57%
Oper. Margin-28.63%
Profit Margin-32.69%
SMA20-1.99%
SMA50-6.60%
SMA200-4.54%
Trades-

Technical

Shs Outstand24.78M
Shs Float1.76M
Short Float0.37%
Short Ratio0.20
Short Interest0.01M
52W High68.00 -78.44%
52W Low5.26 178.71%
Volatility9.90% 10.15%
ATR (14)1.59
RSI (14)46.81
Beta0.57
Rel Volume0.00
Avg Volume32.39K
Volume0

Performance

Perf Week-7.86%
Perf Month-10.50%
Perf Quarter10.23%
Perf Half Y2.16%
Perf YTD-68.27%
Perf Year-75.97%
Perf 3Y-43.62%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price55.00
Prev Close14.66
Price14.66
Change %0.00%

Peers

Mkt cap
TickerCompanyMkt cap
OMHOhmyswift Ltd58.15M
BMGLBasel Medical Group Ltd15.35M
GDTCCytoMed Therapeutics Ltd9.89M
MRMMEDIROM Healthcare Technologies Inc ADR2.06M
ALPSALPS Group Inc50.06M
CELUCelularity Inc23.07M
XWELXWELL Inc5.71M
OSWOneSpaWorld Holdings Limited3.26B
MNDRMobile health Network Solutions1.12M
CUPRCuprina Holdings (Cayman) Ltd9.43M

News

latest 14 of 94
  • EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore (GlobeNewswire)
  • EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products (GlobeNewswire)
  • EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies (GlobeNewswire)
  • EUDA Health Expands Helixe Product Line with Launch of Regenixe iPSC-Derived Skin Stem Cell Secretome Mask (GlobeNewswire) -7.38%
  • EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency (GlobeNewswire)
  • Loading…
  • EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development (GlobeNewswire) -6.69%
  • EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities (GlobeNewswire) +21.09%
  • EUDA Announces Reverse Stock Split of its Ordinary Shares (GlobeNewswire) -15.19%
  • EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant (GlobeNewswire)
  • EUDA Health Announces Second Amendment to Streeterville Warrant Agreement (GlobeNewswire)
  • EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform (GlobeNewswire) -13.93%
  • EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement (GlobeNewswire) +5.70%
  • EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025S22026-02-250.400--0.8376.17--
2025S12025-09-030.000--0.6482.97--
2024Q32024-11-27-0.400-0.400-2.262.261
2024Q22024-08-28-0.400--1.88--
2026S1--0.400-0.327-9.611
2026S2--1.200--17.621
2024Q4---0.400--2.581
2025Q1---0.400--2.961
2025Q2---0.400--3.411
2025Q3---0.200--3.821
2025Q4---0.200--4.171

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-11.600-11.600-9.4625.075.07
2025FY-0.200--0.2009.23-
2026FY-1.600--27.23

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S1S2026-04-151009.619.619.61
2026S1S2026-03-061019.619.619.61
2026S1S2025-11-1110015.6315.6315.63
2026S1S2025-11-1010015.6315.6315.63
2026S1S2025-11-0910015.6315.6315.63
2026S1S2025-11-0810015.6315.6315.63
2026S1S2025-11-0710015.6315.6315.63
2026S1S2025-11-0610015.6315.6315.63
2026S1S2025-11-0510015.6315.6315.63
2026S1S2025-11-0410015.6315.6315.63
2026S1S2025-11-0310015.6315.6315.63
2026S1S2025-11-0210015.6315.6315.63
2026S1S2025-11-0110015.6315.6315.63
2026S1S2025-10-3110015.6315.6315.63

Estimate history

EPS, annual1.869-41.371-8.768-9.462-1.485
Period20212022202320242025
EPS, quarterly-0.095-0.421-0.854-1.8410.018-2.392
PeriodQ4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Sales, annual10.5459.8413.7064.0116.82
Period20212022202320242025
Sales, quarterly000001.699
PeriodQ4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Shares, annual0.4671.011.2311.8581.89
Period20212022202320242025
Shares, quarterly0.4820.5340.5540.55411.0741.01
PeriodQ4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2022FY2021FY2021FY
Total Revenue7.236.824.013.719.840.0010.540.00
Cost of Goods Sold Incl. D&A3.793.833.252.866.490.006.300.00
Gross Profit3.442.990.760.843.350.004.240.00
Selling, General and Administrative Excl. Other5.515.433.344.809.071.995.470.01
Research and Development0.000.00--0.02-0.13-
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.07-2.44-2.58-3.96-5.72-1.99-1.23-0.01
Interest Expense0.240.230.040.020.12-0.130.00
Unusual Expense0.060.0615.204.5919.250.000.000.00
Net Income Before Taxes-2.37-2.73-17.64-8.43-24.93-1.760.95-0.01
Income Taxes-0.010.04-0.000.000.020.000.050.00
Consolidated Net Income-2.36-2.77-17.64-8.43-24.95-1.760.90-0.01
Net Income From Continuing Operations-2.36-2.77-17.60-8.44-24.88-1.760.86-0.01
Net Income-2.36-2.77-15.36-10.04-24.88-1.760.86-0.01
EPS (Recurring)-0.95-1.46-2.90-5.96-18.97-3.181.87-0.02
EPS (Basic, Before Extraordinaries)-1.16-1.48-9.46-8.77-41.37-3.181.87-0.02
EPS (Diluted)-1.16-1.48-9.46-8.77-41.37-3.181.87-0.02
EBITDA-1.66-2.03-2.41-3.85-5.46-1.99-0.96-0.01
Non-Operating Income (Expense)0.000.010.190.130.160.222.300.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio4.700.631.810.440.10-0.43-
Gross Margin47.5743.8819.0022.7234.08-40.25-
Operating Margin-28.63-35.78-64.31-106.87-58.12--11.65-
Net Margin-32.69-40.65-382.88-270.86-252.87-8.20-
Shares Outstanding2.991.891.861.231.010.550.470.51
Market Capitalization43.9043.9086.95-----

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Total Revenue3.473.763.06
Cost of Goods Sold Incl. D&A2.191.612.22
Gross Profit1.282.160.84
Selling, General and Administrative Excl. Other2.043.471.97
Research and Development0.005E-060.00
Other Operating Expense0.000.000.00
Operating Income-0.76-1.31-1.13
Interest Expense0.060.180.04
Unusual Expense0.000.060.00
Net Income Before Taxes-0.85-1.52-1.21
Income Taxes-0.060.05-0.00
Consolidated Net Income-0.80-1.57-1.20
Net Income From Continuing Operations-0.80-1.57-1.20
Net Income-0.80-1.57-1.20
EPS (Recurring)-0.33-0.81-0.65
EPS (Basic, Before Extraordinaries)-0.33-0.84-0.65
EPS (Diluted)-0.33-0.84-0.65
EBITDA-0.57-1.08-0.95
Non-Operating Income (Expense)-0.030.04-0.03
Price To Sales Ratio4.700.64-
Gross Margin36.9657.3427.32
Operating Margin-21.96-34.77-37.03
Net Margin-22.93-41.69-39.38
Shares Outstanding2.991.891.86
Market Capitalization43.9087.34133.02

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2022FY2021FY2021FY
Cash & Short Term Investments0.350.240.190.7886.670.190.00
Short Term Receivables0.330.170.2424.010.004.090.00
Inventories0.000.130.000.000.000.000.00
Other Current Assets0.360.230.300.230.110.070.18
Total Current Assets1.040.760.7225.0386.784.350.18
Net Property, Plant & Equipment0.330.320.210.120.000.160.00
Total Investments and Advances0.000.000.000.000.000.370.00
Long-Term Note Receivable---0.00-1.83-
Intangible Assets0.160.340.000.000.001.280.00
Deferred Tax Assets0.020.03-----
Other Assets0.180.280.380.480.000.000.25
Total Assets1.741.731.3125.6386.788.000.43
Short Term Debt Incl. Current Port. of LT Debt2.331.223.303.860.800.430.00
Accounts Payable0.010.030.001.640.002.820.00
Income Tax Payable0.090.260.210.19-0.31-
Other Current Liabilities3.402.635.2123.443.933.760.40
Total Current Liabilities5.844.148.7229.124.737.320.40
Long Term Debt0.070.050.080.020.000.030.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.100.11---0.05-
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities6.004.308.7929.144.737.400.40
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity-4.25-2.55-7.50-3.5282.050.520.03
Total Shareholders Equity-4.25-2.55-7.50-3.5282.050.520.03
Accumulated Minority Interest-0.01-0.020.020.010.000.080.00
Total Equity-4.27-2.57-7.48-3.5182.050.600.03
Total Liabilities & Stockholders Equity1.741.731.3125.6386.788.000.43
Book Value Per Share-2.25-1.37-6.09-3.49148.181.120.06
Tangible Book Value Per Share-2.34-1.56-6.09-3.49148.18-1.630.06
Full-Time Employees123117106150222
Price to Book Ratio7.35-23.44-----
Return on Assets-159.96-1,157.85-62.65-190.99-3.72--
Return on Equity-----4.27--
Return on Invested Capital-----2.15155.86-28.76
Quick Ratio0.180.150.080.8618.350.590.45
Current Ratio0.180.180.080.8618.350.590.45

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2022FY2021FY2021FY
Net Income-2.36-2.77-17.65-8.14-24.95-1.760.90-0.01
Depreciation0.410.410.170.110.25-0.26-
Other Funds (Non Cash)0.190.1615.254.5822.10-0.22-1.87-
Funds from Operations-1.80-2.20-2.23-3.45-2.65-1.99-0.740.00
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.62-0.230.190.531.120.981.18-
Income Taxes Payable-0.04-0.190.060.09-0.11-0.11-
Cash from Operating Activities-2.42-2.43-2.03-2.92-1.53-1.010.440.00
Capital Expenditures-0.09-0.10-0.120.00-0.020.00-0.000.00
Net Assets From Acquisitions0.000.000.000.00-0.000.00-0.350.00
Sale of Fixed Assets and Businesses0.000.000.020.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-86.250.000.00
Purchase of Investments0.000.000.000.000.00-86.250.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses-0.250.00-0.050.00-0.250.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.34-0.10-0.150.00-0.27-86.25-0.360.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock3.730.100.050.791.1289.170.000.00
Repurchase of Common Pref Stock0.000.000.000.00-1.310.000.000.00
Sale of Common Pref Stock3.730.100.050.792.4289.170.000.00
Proceedsfrom Stock Options3.630.000.050.792.4289.170.000.00
Issuance or Reduction of Debt, Net-1.062.222.161.441.380.80-0.160.00
Change in Long Term Debt-0.01-0.010.000.200.000.000.000.00
Issuance of Long Term Debt0.000.000.000.210.000.000.000.00
Reduction of Long Term Debt-0.01-0.010.00-0.010.000.000.000.00
Net Financing Active Other Cash Flow0.260.230.120.120.00-2.520.000.00
Other Financing Activities Uses---0.14-0.370.00-2.520.000.00
Cash from Financing Activities2.932.552.322.352.4987.45-0.170.00
Exchange Rate Effect0.020.09-0.10-0.02-0.10-0.02-
Net Change in Cash0.190.110.04-0.590.590.19-0.060.00
Free Cash Flow-2.47-2.50-2.13-2.92-1.54-1.010.440.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow------10.21-
Deferred Taxes & Investment Tax Credit-0.00-0.000.00-0.050.00-0.030.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Cash & Short Term Investments0.370.350.18
Short Term Receivables0.800.330.50
Inventories0.010.000.12
Other Current Assets7.840.360.51
Total Current Assets9.021.041.31
Net Property, Plant & Equipment0.430.330.32
Total Investments and Advances0.000.000.00
Intangible Assets0.090.160.26
Deferred Tax Assets0.060.020.04
Other Assets0.130.180.23
Total Assets9.741.742.16
Short Term Debt Incl. Current Port. of LT Debt0.212.332.20
Accounts Payable0.070.010.32
Income Tax Payable0.100.090.16
Other Current Liabilities3.193.403.03
Total Current Liabilities3.575.845.71
Long Term Debt0.130.070.08
Deferred Tax Liabilities0.080.100.10
Other Liabilities0.000.000.00
Total Liabilities3.786.005.89
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity5.98-4.25-3.71
Total Shareholders Equity5.98-4.25-3.71
Accumulated Minority Interest-0.01-0.01-0.02
Total Equity5.96-4.27-3.73
Total Liabilities & Stockholders Equity9.741.742.16
Book Value Per Share2.00-2.25-2.00
Tangible Book Value Per Share1.97-2.34-2.14
Price to Book Ratio7.35-20.53-35.86
Return on Assets-39.72--
Return on Equity-208.62--
Return on Invested Capital-13.03--
Quick Ratio2.530.180.21
Current Ratio2.530.180.23

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Net Income-0.80-1.57-1.20
Depreciation0.190.230.18
Other Funds (Non Cash)0.030.160.00
Funds from Operations-0.64-1.16-1.04
Extraordinary Item0.000.000.00
Changes in Working Capital-0.56-0.06-0.17
Income Taxes Payable0.02-0.06-0.13
Cash from Operating Activities-1.21-1.21-1.22
Capital Expenditures-0.01-0.08-0.02
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments0.000.000.00
Purchase of Investments0.000.000.00
Sale Or Maturity of Investments0.000.000.00
Other Uses-0.250.000.00
Other Sources0.000.000.00
Cash from Investing Activities-0.26-0.08-0.02
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock3.630.100.00
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock3.630.100.00
Proceedsfrom Stock Options3.630.000.00
Issuance or Reduction of Debt, Net-2.221.161.06
Change in Long Term Debt-0.01-0.00-0.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt-0.01-0.00-0.00
Net Financing Active Other Cash Flow0.090.180.06
Other Financing Activities Uses0.00-0.00
Cash from Financing Activities1.491.431.12
Exchange Rate Effect-0.010.030.06
Net Change in Cash0.020.17-0.06
Free Cash Flow-1.21-1.27-1.24

Revenue breakdown

Holistic Wellness Consumer Products and Services2024: 89.02K 2025: 2.45M
Property Management Services2024: 3.92M 2025: 4.37M
Malaysia2024: 89.02K 2025: 1.99M
Singapore2024: 3.92M 2025: 4.83M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.37%0.0M1.8M28.12K
2026-10-150.09%0.0M1.8M18.66K
2026-09-300.04%0.0M1.5M14.11K
2026-09-150.11%0.0M1.5M11.86K
2026-08-310.17%0.0M1.5M5.44K
2026-08-140.12%0.0M1.5M5.91K
2026-07-310.19%0.0M1.3M15.02K
2026-07-150.40%0.0M1.3M123.71K
2026-06-300.25%0.0M1.3M118.56K
2026-06-150.41%0.0M1.3M116.83K
2026-05-290.53%0.0M1.6M118.10K
2026-05-151.31%0.0M1.6M116.62K
2026-04-305.58%0.1M1.6M109.85K
2026-04-150.30%0.0M1.6M8.75K
2026-03-31-0.0M-20.03K
2026-03-130.80%0.0M1.0M27.22K
2026-02-270.43%0.0M1.0M25.35K
2026-02-130.77%0.0M1.0M25.34K
2026-01-300.52%0.0M1.0M24.94K
2026-01-151.27%0.0M1.0M24.11K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-31SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-08-11424B3SEC
2026-08-10EFFECTEffectiveness filing by commission orderSEC
2026-07-31F-3/ASEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-22424B5SEC
2026-07-17F-3/ASEC
2026-07-07F-3/ASEC
2026-06-11424B5SEC
2026-06-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-10SEC
2026-06-08SCHEDULE 13G/ASEC
2026-06-05SCHEDULE 13GSEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-01SEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-31SEC
2026-05-26F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-04-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-28SEC
2026-04-2820-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-27SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-19SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-28SEC
2026-03-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
UBS Group AG0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.03%

OakChart. EUDA. Cached 15 minutes.

Some panels did not load: ratings, insider.